Type

Journal Article

Authors

Norma O'Donovan
John Crown
Michael J Duffy
Naomi Walsh
Kenneth J O'Byrne
Robert O'Connor
Sandra Roche
Kathy Gately
Alex J Eustace
Brendan Corkery
and 2 others

Subjects

Pharmacology

Topics
cell line inhibition triple negative breast cancer cancer treatment pre clinical sensitivity cancer cells clinical trials

Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells. (2019)

Abstract In pre-clinical studies, triple-negative breast cancer (TNBC) cells have demonstrated sensitivity to the multi-targeted kinase inhibitor dasatinib; however, clinical trials with single-agent dasatinib showed limited efficacy in unselected populations of breast cancer, including TNBC. To study potential mechanisms of resistance to dasatinib in TNBC, we established a cell line model of acquired dasatinib resistance (231-DasB). Following an approximately three-month exposure to incrementally increasing concentrations of dasatinib (200 nM to 500 nM) dasatinib, 231-DasB cells were resistant to the agent with a dasatinib IC
Collections Ireland -> Dublin City University -> PubMed

Full list of authors on original publication

Norma O'Donovan, John Crown, Michael J Duffy, Naomi Walsh, Kenneth J O'Byrne, Robert O'Connor, Sandra Roche, Kathy Gately, Alex J Eustace, Brendan Corkery and 2 others

Experts in our system

1
Norma O'Donovan
Dublin City University
Total Publications: 59
 
2
John Crown
Dublin City University
Total Publications: 104
 
3
Michael J Duffy
University College Dublin
 
4
Naomi Walsh
Dublin City University
Total Publications: 22
 
5
Kenneth J O'Byrne
Trinity College Dublin
Total Publications: 37
 
6
Robert O'Connor
Dublin City University
Total Publications: 74
 
7
Sandra Roche
Dublin City University
 
8
Kathy Gately
Trinity College Dublin
Total Publications: 22
 
9
Alex J Eustace
Dublin City University
 
10
B Corkery
Dublin City University
Total Publications: 5